Article · Volume 13, Issue 3 · pp. 885–889

Beyond Seizures: Exploring Cannabidiol in Dravet Syndrome

Priscilla Simon¹, Nair Shreedharsini Rajagopalan¹, Fathima Jahnas¹, Farhana Sudheer¹, Mohammed Ameen Pattambi¹, Sai Keerthana Puthiyedath Cheruvatta¹

¹Department of Pharmacy Practice, Al Shifa College of Pharmacy, Perinthalmanna, Malappuram, Kerala, INDIA.

Abstract

Aim: Dravet Syndrome (DS) is a severe epileptic and developmental encephalopathy causing drug-resistant seizures and developmental delay; this report presents two infant cases and evaluates CBD as adjunct therapy.Materials and Methods: Clinical case details, genetic testing (SCN1A) and treatment response were recorded and monitored.Results: Cannabidiol (CBD) added to regimens provided improved seizure control in refractory cases, with noted adverse effects including somnolence and GI upset.Conclusion: CBD may be beneficial for seizure control in DS but requires careful monitoring and further research on pediatric dosing.

Keywords: Cannabidiol; Dravet syndrome; Pediatric patient; SCN1A Mutation

The full text of this article is available as a PDF. Open the PDF.